KENTON L. LONGENECKER,CHARLES W. HUTCHINS,CHUNG-MING HSIEH,MARK ANDERSON,JIEYI WANG,ARCHANA THAKUR,DEBRA CHAO,QIAN ZHANG,EDWARD B. REILLY,ENRICO L. DIGIAMMARINO,RUSSELL A. JUDGE,DAVID A. EGAN
申请号：
PT13821368
公开号：
PT2935331T
申请日:
2013.12.23
申请国别(地区):
PT
年份:
2018
代理人:
摘要：
The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).
